1차 출처 기록
결정급임상시험 등록 변경
Aura Biosciences: CoMpass 3상 주요 결과 발표 시점 Q4 2027로 조정
The company updated its Phase 3 CoMpass trial guidance, now expecting enrollment completion in 2026 and topline data for the 15-month primary endpoint in Q4 2027. This replaces prior open-ended timelines and reflects slower-than-expected enrollment due to the requirement for documented tumor growth and global site activation challenges.
핵심 사실
출처 발췌
EX-99.1 2 aura-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint Immune Profiling Data Reveal Bel-sar’s Potential to Convert ‘Cold’ to ‘Hot’ Tumors, Supporting a Frontline Therapy Across the Bladder Cancer Spectrum; Phase 1b/2 Trial is on Track for Data Mid-2026 BOSTON, MA – November 13, 2025 – Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the third quarter ended September 30, 2025, and provided recent business